Home > Protocol Summaries: Compounds > dutasteride

Protocol Summaries: dutasteride

Protocol Summaries for dutasteride
GSK
Study ID		 Phase Title Status
103094 Phase 3 ARI103094-Follow-Up Study for REDUCE Study Subjects Not yet recruiting
103500 Phase 4 An observational study to assess the effectiveness of Avodart™(dutasteride)in subjects with benign prostatic hyperplasia in day to day clinical practice Completed
104274 Phase 4 See Detailed Description Completed
106377 Phase 3 An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton classification type IIIv, IV and V) Completed
112597 Phase 4 Avodart Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence (A prospective patient and provider study) Recruiting
112598 Phase 4 Adherence of patients taking 5ARI vs 5ARI + alpha blocker combination therapy in Enlarged Prostate Completed
112599 Phase 4 Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment Completed
113074 Phase 4 Value of Early 5-alpha-reductase Inhibitor (5ARI) Treatment in Patients Receiving Combination 5ARI and Alpha-Blocker (AB) Therapy for Enlarged Prostate (EP) Completed
113797 Phase 4 An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and effectiveness of AVODART® administered in Korean androgenetic alopecia patients according to the prescribing information Recruiting
113979 Phase 3 Economic Analyses Alongside the REDUCE Clinical Trial Not yet recruiting
ARI105326 phase 3 Clinical Evaluation of GI198745 in Benign Prostatic Hyperplasia- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 in Patients with Benign Prostatic Hyperplasia Completed
ARI106807 Phase 4 A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 weeks to Reduce The Risk of Acute Urinary Retention Relapse Following Successful Trial Without Catheter. Terminated
ARI108898 phase 3 A randomized, double-blind, placebo-controlled, six-month parallel-group study to assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH), followed by a 12-month open-label treatment phase Completed
ARI109882 Phase 1 See Detailed Description Completed
ARI109924 Phase 2 A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemical Failure (PSA increase) after Radical Therapy with Curative Intent Active, not recruiting
ARI111402 Phase 1 An open label, randomized, repeat dose, 3 period cross over study to determine the bioequivalence of 3 different formulations of tamsulosin at steady state in healthy male volunteers Completed
ARI30016 Phase 2 A Long-term Extension Study of GI198745 in Subjects with Benign Prostatic Hyperplasia Completed
ARI40005 phase 3 See Detailed Description Completed
ARI40006 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer Completed
ARI40014 Phase 4 Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels Completed
AVO105948 Phase 4 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management Active, not recruiting
AVO108943 Phase 4 A Randomized Double-Blind Parallel Group Study Comparing Casodex 50mg plus Placebo to Casodex 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Active, not recruiting
TDC106220 Phase 2 A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered with 0.25mg Dutasteride Compared with 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism Completed

Filter list by: